Abstract
Diabetic nephropathy is a syndrome of albuminuria, declining glomerular filtration rate (GFR), arterial hypertension, and increased cardiovascular risk that affects 20–40% of type 1 (insulin‐dependent) and type 2 (non insulin dependent) diabetic patients [1–3]. Diabetics, mostly type 2, account for about one third of all patients requiring chronic renal replacement therapy in western countries. Indeed, type 2 diabetics with end‐stage renal disease (ESRD) are rapidly increasing because of the continuing increase in the prevalence of type 2 diabetes and the progressively declining mortality rate from cardiovascular causes. The costs associated with management of the disease (in 1996, $4.6 billion in the United States alone) are increasing in proportion and will soon become unbearable for most western countries. High mortality, costs, and decreased quality of life associated with chronic renal replacement therapy, have motivated the search for the causes and the possible treatments that might effectively delay or even completely prevent the progression of diabetic nephropathy to ESRD.

This publication has 18 references indexed in Scilit: